Last Updated on November 11, 2024 by The Health Master
Hikal’s pharma manufacturing facility located at Panoli, Gujarat, was recently inspected by the US Food and Drug Administration (USFDA) in compliance with their requirements.
The five-day preapproval inspection of an API was conducted from May 8-12, 2023 was concluded with ‘Zero 483 observations’ from the USFDA.
The Panoli facility was earlier audited twice by the USFDA and successfully approved for manufacturing advanced intermediates and key starting materials.
USFDA issues Form 483 with 3 observation to Zydus, Ahmedabad
USFDA issues Form 483 with zero observation to Piramal
USFDA issues Form 483 with 10 observations to Lupin, Pithampur
USFDA issues Form 483 with 2 observations to Alembic, Gujarat
USFDA issues Form 483 with 3 observations to Bliss GVS Pharma, Maharashtra
USFDA issues Form 483 with one observation to Torrent, Gujarat
Govt amends Para 5 and Para 18 of DPCO 2013
USFDA issues marketing denial for 6,500 flavored E-cigarettes
Mizoram chalks out strategy to develop Pharma Cluster
USFDA gives approval for Brexpiprazole
Surprise Inspection of 35 Medical Store: 8 Suspended, One Sealed
Govt releases Guidelines for scheme for Assistance to Medical Devices Clusters
FDA Haryana busts international racket selling spurious cancer injection, 4 arrested
Requirement of IP, IPRS & Impurity Standards to be part of joint inspection
